Press Releases
// May 14, 2026
ElevateBio Data at ASGCT 29th Annual Meeting Showcase Expanded Gene Editing Platform and Services Spanning New Modalities, AI Discovery, and LNP Delivery
// Apr 27, 2026
ElevateBio to Present Nine Abstracts Showcasing Advancements Across its Gene Editing Platform at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
// Jan 08, 2026
ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business
// Jan 05, 2026
ElevateBio Appoints Christopher Murphy as Chief Executive Officer and Member of the Board of Directors
// Aug 13, 2025
ElevateBio BaseCamp Achieves ICMC™ Certification for Commercial Cell and Gene Therapy Manufacturing Capabilities
// May 12, 2025
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
// Apr 28, 2025
ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
// Apr 28, 2025
ElevateBio Announces Transition of David Hallal to Executive Chairman of the Board of Directors
// Mar 10, 2025
ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI
// Feb 24, 2025
ElevateBio Announces Compelling Preclinical Data Demonstrating the Potential of LETI-101 as a Treatment for Huntington’s Disease
// Jan 09, 2025
